New trial
Phase I/II AZD9829: CD123-directed mAb Topo1 inhibitor ADC
- Trial ID
- NCT06179511 on ClinicalTrials.gov
- Cancer type
- Hematologic Malignancies
- Stage of research
- First-in-human
- Location
- 24 Locations
- Published in
- New in Oncology - June 23, 2025
This open-label, multicenter study assesses the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD9829 administered intravenously as monotherapy or in combination. It enrolls patients with relapsed/refractory CD123-positive hematologic malignancies, including AML and MDS, at global sites coordinated by AstraZeneca.
More in other blood cancers and transplant
-
Trial result · Aug 13, 2026 · NCT04904588
Standard-dose PTCy enables mismatched-donor HCT but carries substantial early infection burden -
Trial result · Aug 6, 2026 · NCT05388123
Low-dose vemurafenib (BRAF V600E inhibitor) + rituximab drives 73% CR with zero grade 3-4 AEs in HCL -
Trial result · Aug 6, 2026 · NCT02113982
Tagraxofusp (CD123-directed cytotoxin) in BPDCN delivers 71%–90% ORR across trials—HSCT bridge drives survival -
New trial · Jun 25, 2026 · NCT07634536
Phase 2 automated VMAT-based TMLI conditioning refines marrow / lymphoid-targeted irradiation for allo-HCT. -
New trial · Jun 25, 2026 · NCT07572006
Phase 1 JNJ-95804306 (no disclosed MOA/target) in relapsed/refractory AML/MDS and CLL/SLL